Phase I dendritic cell p53 peptide vaccine for head and neck cancer
PJ Schuler, M Harasymczuk, C Visus, A DeLeo… - Clinical Cancer …, 2014 - AACR
Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
creates a targetable tumor antigen. Adjuvant dendritic cell (DC)–based vaccination against …
Generation of T cells specific for the wild-type sequence p53264–272 peptide in cancer patients: implications for immunoselection of epitope loss variants
TK Hoffmann, K Nakano, EM Elder… - The Journal of …, 2000 - journals.aai.org
Alterations in the p53 gene occur frequently and can lead to accumulation of p53 protein in
squamous cell carcinomas of the head and neck (SCCHN). Since accumulation of p53 is …
squamous cell carcinomas of the head and neck (SCCHN). Since accumulation of p53 is …
Phase I/II pilot study of Wilms' tumor 1 peptide‐pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer
M Ogasawara, M Miyashita… - … Apheresis and Dialysis, 2019 - Wiley Online Library
The prognosis of metastatic or relapsed head and neck squamous cell carcinoma (HNSCC)
remains poor despite the introduction of immune checkpoint blockade agents. We aimed to …
remains poor despite the introduction of immune checkpoint blockade agents. We aimed to …
Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
IM Svane, AE Pedersen, HE Johnsen… - Cancer Immunology …, 2004 - Springer
Peptides derived from over-expressed p53 protein are presented by class I MHC molecules
and may act as tumour-associated epitopes. Due to the diversity of p53 mutations …
and may act as tumour-associated epitopes. Due to the diversity of p53 mutations …
p53110–124-specific Human CD4+ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8+ T Cells
K Chikamatsu, A Albers, J Stanson, WW Kwok… - Cancer Research, 2003 - AACR
Current evidence suggests that the optimal vaccines for cancer should incorporate tumor-
specific cytotoxic as well as helper epitopes. Wild-type sequence (wt) p53 peptides are …
specific cytotoxic as well as helper epitopes. Wild-type sequence (wt) p53 peptides are …
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells
K Chikamatsu, K Nakano, WJ Storkus, E Appella… - Clinical Cancer …, 1999 - AACR
CTLs recognizing the HLA-A2. 1-restricted, wild-type sequence p53 epitopes p53149–157
and p53264–272 were generated from CD8-enriched populations of nonadherent …
and p53264–272 were generated from CD8-enriched populations of nonadherent …
Development of vaccines against self-antigens: the p53 paradigm.
S Chada, A Mhashilkar, JA Roth… - Current opinion in drug …, 2003 - europepmc.org
Active immunotherapy using dendritic cells (DCs) to deliver tumor antigens has generated
considerable excitement among oncologists worldwide. Although most tumor antigens used …
considerable excitement among oncologists worldwide. Although most tumor antigens used …
Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients
EY Nikitina, JI Clark, J Van Beynen, S Chada… - Clinical cancer …, 2001 - AACR
Accumulation of wild-type or mutant p53 protein occurs in∼ 50% of human malignancies.
This overexpression may generate antigenic epitopes recognized by CTLs. Because normal …
This overexpression may generate antigenic epitopes recognized by CTLs. Because normal …
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of …
IM Svane, AE Pedersen, JS Johansen… - Cancer Immunology …, 2007 - Springer
Abstract p53 mutations are found in up to 30% of breast cancers and peptides derived from
over-expressed p53 protein are presented by class I HLA molecules and may act as tumor …
over-expressed p53 protein are presented by class I HLA molecules and may act as tumor …
A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck
M Eura, K Chikamatsu, F Katsura, A Obata… - Clinical Cancer …, 2000 - AACR
Evidence has accumulated indicating that HLA-A2-restricted CTLs specific for human wild-
type sequence p53 epitopes lyse tumor cells expressing mutant p53. To explore the …
type sequence p53 epitopes lyse tumor cells expressing mutant p53. To explore the …
相关搜索
- cell carcinomas head and neck
- neck cancer cell vaccination
- neck cancer patients with head
- cancer patients dendritic cells
- p53 peptide breast cancer
- patients with head cell vaccination
- hla a24 head and neck
- p53 paradigm development of vaccines
- cytotoxic t lymphocytes head and neck
- peripheral blood dendritic cells
- cancer patients generation of t cells